SecurityMRNS / Marinus Pharmaceuticals, Inc. (56854Q101)
CEOCashman Christopher Michael
IndustryPharmaceutical Preparations
Institutional Owners66
Institutional Shares23,037,597 - 56.85%
Common Stock Shares Outstanding40,520,705 shares (as of 2018-03-31)
Institutional Value$ 87,524,000 USD

Institutional Stock Ownership and Shareholders()

MRNS / Marinus Pharmaceuticals, Inc. Institutional Ownership

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has 66 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23,037,597 shares. Largest shareholders include Bain Capital Life Sciences Investors, Llc, Jennison Associates Llc, Granite Point Capital Management, L.P., Franklin Resources Inc, Vanguard Group Inc, GMT Capital Corp, 683 Capital Management, LLC, Three Bays Capital Lp, Perceptive Advisors Llc, and BlackRock Inc..
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/mrns"><img src="https://images.fintel.io/us-mrns-so.png" alt="MRNS / Marinus Pharmaceuticals, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR/A Sabby Management, LLC Call 451 172
2018-05-15 13F-HR DEUTSCHE BANK AG\ 416,215 340,382 -18.22 3,396 1,299 -61.75
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 7,312 5,630 -23.00 60 22 -63.33
2018-05-10 13F-HR Artal Group S.A. 200,000 500,000 150.00 1,632 1,910 17.03
2018-05-03 13F-HR DekaBank Deutsche Girozentrale 17,000 60
2018-04-18 13F-HR/A FNY Partners Fund LP 22,500 0 -100.00 183 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 0 97,716 0 373
2018-05-14 13F-HR MORGAN STANLEY 0 12,844 0 49
2018-05-14 13F-HR Renaissance Technologies LLC 611,677 420,400 -31.27 4,991 1,606 -67.82
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 132,054 0 -100.00 1,117 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 259 2
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. Call 56,500 0 -100.00 461 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 1,022,113 16,729 -98.36 8,340 64 -99.23
2018-05-15 13F-HR Arrowpoint Asset Management, LLC 10,735 10,735 0.00 88 41 -53.41
2018-04-20 13F-HR Cable Hill Partners, LLC 6,000 24
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 915,620 579,139 -36.75 7,471 2,212 -70.39
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 117,025 0 -100.00 955 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 37,344 147,229 294.25 305 562 84.26
2017-02-10 13F-HR BlackRock Investment Management, LLC 2,024 2,024 0.00 4 2 -50.00
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 1,001,000 0 -100.00 8,168 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 1,271,322 1,301,219 2.35 10,374 4,971 -52.08
2018-05-15 13F-HR Invesco Ltd. 13,035 50
2018-05-15 13F-HR GMT Capital Corp 1,266,899 4,840
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 68,162 406,191 495.92 556 1,552 179.14
2018-05-15 13F-HR NEXTHERA CAPITAL LP 925,327 0 -100.00 7,551 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 33,209 36,697 10.50 271 140 -48.34
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 115,600 279,000 141.35 943 1,066 13.04
2018-05-15 13F-HR Schonfeld Strategic Advisors LLC 211,886 0 -100.00 1,729 0 -100.00
2018-05-15 13F-HR Krilogy Financial LLC 7,400 28
2018-05-15 13F-HR Granite Point Capital Management, L.P. 2,278,848 2,638,321 15.77 18,595 10,078 -45.80
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 907,732 907,732 0.00 7,407 3,467 -53.19
2018-05-15 13F-HR Iguana Healthcare Management, LLC 100,000 100,000 0.00 816 382 -53.19
2018-05-15 13F-HR Adage Capital Partners GP LLC 567,000 0 -100.00 4,627 0 -100.00
2018-05-15 13F-HR Cormorant Asset Management, LLC 500,000 478,111 -4.38 4,080 1,826 -55.25
2018-05-15 13F-HR Capital Bank & Trust Co 4,120 4,120 0.00 34 16 -52.94
2018-05-15 13F-HR BlueCrest Capital Management Ltd 32,487 124
2018-05-11 13F-HR Cutler Group LP Call 2,800 6,100 117.86 6 0 -100.00
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 15,100 15,100 0.00 123 58 -52.85
2018-05-15 13F-HR Bain Capital Life Sciences Investors, Llc 3,977,453 3,977,453 0.00 32,456 15,194 -53.19
2018-05-15 13F-HR Shanda Payment Holdings Ltd. 10,000 10,000 0.00 82 38 -53.66
2018-05-15 13F-HR Verition Fund Management LLC 14,241 54
2018-05-15 13F-HR Granite Point Capital Management, L.P. Call 549,900 2,101
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 16,300 62
2018-05-10 13F-HR FRED ALGER MANAGEMENT INC 18,000 69
2018-05-15 13F-HR Squarepoint Ops LLC 19,378 0 -100.00 158 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 60,501 232
2018-05-11 13F-HR Delpha Capital Management, Llc 2,922 0 -100.00 24 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 50,472 53,309 5.62 412 204 -50.49
2018-05-15 13F-HR UBS Group AG 13 0 -100.00 0 0
2018-05-15 13F-HR ORBIMED ADVISORS LLC 567,600 567,600 0.00 4,632 2,168 -53.20
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 20,500 0 -100.00 167 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 34,277 42,019 22.59 279 160 -42.65
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 16,300 62
2018-06-04 13F-HR Eam Global Investors Llc 110,968 0 -100.00 905 0 -100.00
2018-05-11 13F-HR HAP Trading, LLC Put 625,000 1,094
2018-05-14 13F-HR ProShare Advisors LLC 21,782 18,692 -14.19 178 71 -60.11
2018-04-20 13F-HR JENNISON ASSOCIATES LLC 2,696,553 2,735,623 1.45 22,004 10,450 -52.51
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 27,523 28,396 3.17 225 108 -52.00
2018-05-11 13F-HR HAP Trading, LLC 379,612 1,450
2018-05-14 13F-HR VIRTUS ETF ADVISERS LLC 37,803 80,389 112.65 308 307 -0.32
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Put 25,900 99
2018-05-02 13F-HR Daiwa Securities Group Inc. 223 1
2018-05-15 13F-HR J. Goldman & Co LP 6,528 0 -100.00 53 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 22,956 116,511 407.54 42 118 180.95
2018-05-03 13F-HR Trexquant Investment LP 28,237 0 -100.00 230 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 5,800 182,900 3,053.45 47 699 1,387.23
2018-06-14 13F-HR/A Dynamic Technology Lab Private Ltd 17,964 0 -100.00 146 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 86,253 101,703 17.91 157 103 -34.39
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 416,300 0 -100.00 3,397 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 28,700 40
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,468 1,612 9.81 12 6 -50.00
2018-05-15 13F-HR ELLINGTON MANAGEMENT GROUP LLC 40,500 0 -100.00 330 0 -100.00
2018-05-14 13F-HR Holistic Financial Partners 265 265 0.00 2 1 -50.00
2018-05-10 13F-HR FRANKLIN RESOURCES INC 2,147,385 1,667,585 -22.34 17,523 6,370 -63.65
2018-05-09 13F-HR BlackRock Inc. 672,485 635,838 -5.45 5,487 2,429 -55.73
2018-05-15 13F-HR A.R.T. Advisors, LLC 126,952 43,828 -65.48 1,035 167 -83.86
2018-05-15 13F-HR Atika Capital Management LLC Call 150,000 0 -100.00 1,224 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 25,900 227,700 779.15 211 870 312.32
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 4,780 122,744 2,467.87 39 469 1,102.56
2018-05-11 13F-HR CITIGROUP INC 1,277 178 -86.06 10 1 -90.00
2018-05-09 13F-HR IFP Advisors, Inc 200 1
2018-02-09 13F-HR RidgeWorth Capital Management LLC 37,803 308
2018-05-14 13F-HR EAM Investors, LLC 192,787 0 -100.00 1,573 0 -100.00
2018-05-11 13F-HR Cutler Group LP 2,200 21,400 872.73 17 81 376.47
2018-05-11 13F-HR CITADEL ADVISORS LLC 16,729 64
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 9,200 101,900 1,007.61 75 389 418.67
2018-05-15 13F-HR THREE BAYS CAPITAL LP 944,300 3,607
2018-05-15 13F-HR/A CAXTON CORP 18,643 26,827 43.90 152 102 -32.89
2018-05-11 13F-HR CITADEL ADVISORS LLC Put 25,900 99
2018-05-11 13F-HR TD ASSET MANAGEMENT INC 16,800 0 -100.00 137 0 -100.00
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. Put 38,100 0 -100.00 311 0 -100.00
2018-05-15 13F-HR New Leaf Venture Partners, L.L.C. 425,000 342,550 -19.40 3,468 1,309 -62.25
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 164,060 164,060 0.00 1,338 626 -53.21
2018-05-15 13F-HR FARALLON CAPITAL MANAGEMENT LLC 895,000 0 -100.00 7,303 0 -100.00
2018-05-15 13F-HR 683 Capital Management, LLC 550,000 1,200,000 118.18 4,488 4,584 2.14
2018-05-15 13F-HR Marshall Wace North America L.P. 22,239 95,560 329.70 181 365 101.66
2018-05-11 13F-HR Quantbot Technologies LP 8,177 2,148 -73.73 66 8 -87.88
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,719 361 -79.00 14 1 -92.86
2018-05-15 13F-HR Jefferies Group LLC 24,900 95
2018-04-26 13F-HR SIMPLEX TRADING, LLC 2,015 50,258 2,394.19 16 191 1,093.75
2018-05-15 13F-HR J. Goldman & Co LP Call 30,600 0 -100.00 250 0 -100.00
2018-05-14 13F-HR ASCEND CAPITAL, LLC 1,012,854 0 -100.00 8,264 0 -100.00
2018-05-14 13F-HR Pacad Investment Ltd. 7,000 58,500 735.71 57 207 263.16
2018-05-14 13F-HR BlueMountain Capital Management, LLC 12,280 47
MRNS: Marinus Pharmaceuticals Analysis and Research Report

2018-04-27 - Asif

Overview Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors. The company's Pipeline Marinus Pharmaceuticals is developing ganaxolone to treat children suffering from rare epilepsies and both adults and children suffering from other neuropsychiatric conditions where there is a mechanistic rationale for ganaxolo...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

9h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

GW Pharmaceuticals: Value Beyond Epidiolex?

2018-06-04 seekingalpha
GW has Sativex ready for a Phase 3 study in an indication that already has approval in several countries outside of the US. (120-0)

How To Use Probabilities In Investing: Open Sources

2018-05-11 seekingalpha
(In whose favor are the odds of this particular game, hmm? Image by Own work, CC BY-SA 3.0, source) (83-0)

BRIEF-Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15

2018-05-02 reuters
* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017 (71-0)

Ovid Therapeutics: Beaten Down IPO With Upcoming 2018 Catalysts

2018-05-01 seekingalpha
Data from the phase 2 STARS trial for OV101 in Angelman’s syndrome is expected in Q3, 2018. (204-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: March 15, 2018

2018-03-16 seekingalpha
The small pullback in the U.S. biotechnology indexes (IBB) (XBI) after a run-up from the recent correction lows looks almost complete and we expect the uptrend to resume soon. (143-0)

CUSIP: 56854Q101